CO2023000130A2 - Composición y método para el tratamiento del dolor crónico - Google Patents

Composición y método para el tratamiento del dolor crónico

Info

Publication number
CO2023000130A2
CO2023000130A2 CONC2023/0000130A CO2023000130A CO2023000130A2 CO 2023000130 A2 CO2023000130 A2 CO 2023000130A2 CO 2023000130 A CO2023000130 A CO 2023000130A CO 2023000130 A2 CO2023000130 A2 CO 2023000130A2
Authority
CO
Colombia
Prior art keywords
chronic pain
treatment
composition
relates
cannabigerol
Prior art date
Application number
CONC2023/0000130A
Other languages
English (en)
Inventor
Richard Hopkins
Meghan Gail Thomas
Oludare Odumosu
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901947A external-priority patent/AU2020901947A0/en
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of CO2023000130A2 publication Critical patent/CO2023000130A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden Δ9-tetrahidrocannabinol (THC), cannabidiol (CBD) y cannabigerol (CBG) y un componente terpeno, y su uso en el tratamiento del dolor crónico. La invención también se refiere a métodos para tratar el dolor crónico, especialmente el dolor crónico en atletas.
CONC2023/0000130A 2020-06-12 2023-01-06 Composición y método para el tratamiento del dolor crónico CO2023000130A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020901947A AU2020901947A0 (en) 2020-06-12 Composition and method for treating chronic pain
PCT/AU2021/050602 WO2021248207A1 (en) 2020-06-12 2021-06-11 Composition and method for treating chronic pain

Publications (1)

Publication Number Publication Date
CO2023000130A2 true CO2023000130A2 (es) 2023-05-19

Family

ID=78523907

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000130A CO2023000130A2 (es) 2020-06-12 2023-01-06 Composición y método para el tratamiento del dolor crónico

Country Status (14)

Country Link
US (1) US20230218566A1 (es)
EP (1) EP4164628A1 (es)
JP (1) JP2023529476A (es)
KR (1) KR20230069080A (es)
CN (1) CN115843248A (es)
AU (1) AU2021215262B2 (es)
BR (1) BR112022025302A2 (es)
CA (1) CA3186718A1 (es)
CL (1) CL2022003507A1 (es)
CO (1) CO2023000130A2 (es)
IL (1) IL299008A (es)
MX (1) MX2022015799A (es)
PE (1) PE20230837A1 (es)
WO (1) WO2021248207A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220387256A1 (en) * 2021-06-03 2022-12-08 Kent Byron Vial With Metered Dispenser

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023166A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
WO2019056128A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations COMPOSITIONS COMPRISING CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENES AND FLAVONOIDS AND THEIR USE IN THE TREATMENT OF INSOMNIA
EP3703672A4 (en) * 2017-10-30 2021-12-01 Endocanna Health, Inc. CANNABINOID FORMULATIONS
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use
AU2019251357B2 (en) * 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
EP3876918A4 (en) * 2018-11-09 2022-08-10 Cronos Group Inc. LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods

Also Published As

Publication number Publication date
EP4164628A1 (en) 2023-04-19
WO2021248207A1 (en) 2021-12-16
JP2023529476A (ja) 2023-07-10
CL2022003507A1 (es) 2023-06-09
KR20230069080A (ko) 2023-05-18
AU2021215262A1 (en) 2021-11-04
PE20230837A1 (es) 2023-05-19
CA3186718A1 (en) 2021-12-16
US20230218566A1 (en) 2023-07-13
IL299008A (en) 2023-02-01
BR112022025302A2 (pt) 2023-02-28
CN115843248A (zh) 2023-03-24
AU2021215262B2 (en) 2023-12-14
MX2022015799A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
Farid et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis
CO2019013887A2 (es) Composiciones y tratamientos para el trastorno del sueño
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
BR112019001794A2 (pt) composição de cannabis
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
BR112017027836A2 (pt) método para o tratamento de inflamação usando compostos naturais e/ou dieta
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
MX2023006561A (es) Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
BRPI0913665B8 (pt) composição para tratamento de pressão intraocular aumentada em um paciente, compreendendo extratos de vaccinum myrtillus e de casca de pinheiro
EA201891752A2 (ru) Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования
BR112022021640A2 (pt) Usos e formulações de canabinoides
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
CL2021001076A1 (es) Composición farmacéutica que comprende una combinación de 1,3-2,5% de tetrahidrocannabinol (thc) y 0,6-1,4% de cannabidiol (cbd); su proceso de elaboración; y su uso para el tratamiento del dolor crónico refractario.
BR112022016551A2 (pt) Inibidor de atividade de cxcl8 (interleucina-8) e combinação de corticosteroide e composição farmacêutica e uso dos mesmos
CO2022011987A2 (es) Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol
BR112023020839A2 (pt) Método in vitro para determinar a eficácia do tratamento de um indivíduo com um distúrbio mental, composição farmacêutica, cápsula e uso de canabidiol ou de uma composição farmacêutica compreendendo canabidiol